CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Medical Officer sold 10,853 shares at $36.57 ($396,894)
- 4 Planned sale Chief Executive Officer sold 31,550 shares at $36.57 ($1,153,784)
- 4 Planned sale Chief Commercial Officer sold 3,097 shares at $36.57 ($113,257)
- 4 Planned sale Chief Legal Officer sold 14,051 shares at $36.57 ($513,845)
- 4 Planned sale Chief Financial Officer sold 3,377 shares at $36.57 ($123,497)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Option exercise Director acquired 1,086 shares (option exercise)
- 4 Option exercise Director acquired 1,629 shares (option exercise)
- 4 Grant or award Chief Medical Officer acquired 200,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 125,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 125,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 125,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 750,000 shares (grant or award)
Page 1 of 26 · 506 filings